anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Alkermes · conference-presentation

Alkermes | Results Presentation Deck | 24 slides

24 pages · 3 arc beats · 1 loops

Conference-Presentation Download JSON
Unlock

Alkermes | Results Presentation Deck | 24 slides

Alkermes · 2023-02
arc beats above · slides in the middle · loops below · scroll → 1 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

3
coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Market Size and Performance 2 slides 100% 2/2 slides 100% 2/2 slides · 4 hits
— 0/2 slides
50% 1/2 slides
— 0/2 slides
100% 2/2 slides
— 0/2 slides
Financial Results 3 slides 100% 3/3 slides 100% 3/3 slides · 11 hits
— 0/3 slides
100% 3/3 slides · 5 hits
— 0/3 slides
100% 3/3 slides
— 0/3 slides
2023 Outlook and Planned Separation 5 slides 100% 5/5 slides 100% 5/5 slides · 17 hits
— 0/5 slides
60% 3/5 slides 20% 1/5 slides 100% 5/5 slides 20% 1/5 slides

Slide inventory

24
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detail
02
other
Open slide detail
03
front_matter
Open slide detail
04
front_matter
Open slide detailBeat · Market Size and Performance
05
analyze_data
Open slide detailBeat · Market Size and Performance
06
The chart tracks TRx (Total Prescriptions) over 67 weeks.analyze_data
Open slide detail
07
analyze_data
Open slide detail
08
The chart includes a vertical dashed line separating 2021 and 2022 data.analyze_data
Open slide detail
09
The chart uses a vertical bar format to visualize quarterly trends in TRx MOT.analyze_data
Open slide detail
10
Includes a disclaimer at the bottom regarding the forward-looking nature of the expectations.analyze_data
Open slide detail
11
transition
Open slide detail
12
Includes footnotes regarding non-GAAP reconciliation and INVEGA product royalty revenue decline.analyze_data
Open slide detailBeat · Financial Results
13
Includes a highlighted column for Q4'22 and detailed footnotes regarding specific product revenue drivers.analyze_data
Open slide detailBeat · Financial Results
14
Includes a blue box highlight around the FY 2022 column. Contains footnotes regarding rounding, product inclusions, and specific revenue drivers.analyze_data
Open slide detailBeat · Financial Results
15
The slide includes both GAAP and non-GAAP financial measures with a disclaimer regarding reconciliation.analyze_data
Open slide detailBeat · 2023 Outlook and Planned Separation
16
The slide includes a disclaimer regarding the nature of the expectations and the date of the guidance.analyze_data
Open slide detailBeat · 2023 Outlook and Planned Separation
17
Includes disclaimer regarding non-GAAP measures and business separation context.analyze_data
Open slide detailBeat · 2023 Outlook and Planned Separation
18
transition
Open slide detailBeat · 2023 Outlook and Planned Separation
19
prioritize
Open slide detailBeat · 2023 Outlook and Planned SeparationLoop · Cost Of Inaction
20
The slide outlines the strategic focus of the company following the spin-off of its oncology business.summarize
Open slide detailLoop · Cost Of Inaction
21
appendix
Open slide detail
22
The table reconciles a GAAP net loss of $158.3M to a non-GAAP net income of $57.9M.analyze_data
Open slide detail
23
Includes share count and per share data adjustments.analyze_data
Open slide detail
24
closing_ask
Open slide detail